The healthcare sector is heterogeneous, with a wide dispersion in returns between the best- and worst-performing stocks.

Speaking about IIT Guwahati's commitment to developing cutting-edge biotechnologies, Prof. Devendra Jalihal, Director, IIT Guwahati, said, "IIT Guwahati is committed to advancing research that creates ...

Though most biopharma investment is in two states, follow this model to bring the research—and investments—elsewhere.

The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

A wave of startups is are turning innovation into advantage, pioneering solutions to challenges presented by chocolate and cheese to coffee and packaging ...

Discover two undervalued dividend stocks challenging the 60/40 rule. Enjoy strong returns, inflation protection & income ...